Lacosamide
Approved · FDA / EMAAlso known as (+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE, (2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide, (R)-2-acetamido-N-benzyl-3- methoxypropionamide, (R)-LACOSAMIDE 1+5 more
(+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE, (2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide, (R)-2-acetamido-N-benzyl-3- methoxypropionamide, (R)-LACOSAMIDE 1, Erlosamide, Motpoly, Vimpat, Lacosamida, Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Supplemental approval: LACOSAMIDE (ANDA204921)
Approval: LACOSAMIDE (ANDA217596)
Label change: LACOSAMIDE (ANDA205006)
Effects of lacosamide and carbamazepine on lipids in a randomized trial.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years… Show full indicationShow less
Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. Lacosamide Adroiq is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
Indication: Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and… Show full indicationShow less
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Indication: Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years… Show full indicationShow less
Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. Lacosamide Accord is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- Epilepsia3
- Epilepsia open2
- Epilepsy research2
- Acta neurologica Scandinavica1
- Epileptic disorders : international epilepsy journal with videotape1
- European journal of pain (London, England)1
- De Backer M4
- Doty P4
- Baulac M3
- Beller C3
- Roebling R3
- Isojarvi J2
- McClung C2
- McShea C2
- Pitié-Salpêtrière Hospital2
- Dnipro City Pediatric Clinical Hospital1
- Duke University Medical Center1
- Epilepsy Centre Frankfurt Rhine-Main1
- George Emil Palade University of Medicine1
- Hospital Vall d'Hebron1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.